

**SUPPLEMENTAL Table 1.** Factors associated with 28-day mortality, univariate analysis

Variable	Survived (n=351)	Exitus (n=466)	P value
<b>Age, years (mean±SD)</b>	61.14±17.80	67.67±15.87	<0.001
<65, n (%)	183 (53.2)	161 (46.8)	
65-74, n (%)	81 (39.7)	123 (60.3)	<0.001
75-84, n (%)	61 (33.0)	124 (67.0)	
≥85, n (%)	26 (31.0)	58 (69.0)	
<b>Gender</b>			
Female, n (%)	166 (41.6)	233 (58.4)	0.444
Male, n (%), n (%)	185 (44.3)	233 (55.7)	
<b>Vaccination status</b>			
Unvaccinated, n (%)	209 (43.2)	275 (56.8)	0.878
2 doses CoronoVac, n (%)	142 (42.6)	191 (57.4)	
<b>Body mass index (kg/m<sup>2</sup>), median (IQR)</b>	27.0 (24.2-30.1)	26.8 (24.0-29.9)	
<b>Obesity</b>			
Yes, n (%)	98 (46.0)	115 (54.0)	0.296
No, n (%)	253 (41.9)	351 (58.1)	
<b>Comorbid diseases</b>			
<b>Hypertension</b>			
Yes, n (%)	146 (38.4)	234 (61.6)	0.014
No, n (%)	205 (46.9)	232 (53.1)	
<b>Diabetes mellitus</b>			
Yes, n (%)	89 (37.9)	146 (62.1)	0.062
No, n (%)	262 (45.0)	320 (55.0)	
<b>Coronary artery disease</b>			
Yes, n (%)	49 (40.8)	71 (59.2)	0.610
No, n (%)	302 (43.3)	395 (56.7)	
<b>Congestive heart failure</b>			
Yes, n (%)	24 (36.4)	42 (63.6)	0.259
No, n (%)	327 (43.5)	424 (56.5)	
<b>COPD</b>			
Yes, n (%)	27 (34.6)	51 (65.4)	0.117
No, n (%)	324 (43.8)	415 (56.2)	
<b>Cerebrovascular disease</b>			
Yes, n (%)	21 (44.7)	26 (55.3)	0.806
No, n (%)	330 (42.9)	440 (57.1)	
<b>Chronic renal failure</b>	11 (30.6)	25 (69.4)	
Yes, n (%)	11 (30.6)	25 (69.4)	0.124
No, n (%)	340 (43.5)	441 (56.5)	
<b>Malignancy</b>			
Yes, n (%)	19 (33.9)	37 (66.1)	0.157
No, n (%)	332 (43.6)	429 (56.4)	
<b>Dementia</b>			
Yes, n (%)	16 (42.1)	22 (57.9)	0.913
No, n (%)	335 (43.0)	444 (57.0)	
<b>Number of comorbidities</b>			
No comorbidity, n (%)	121 (56.5)	93 (43.5)	<0.001
1 comorbidity, n (%)	90 (39.1)	140 (60.9)	
2 comorbidity, n (%)	83 (39.2)	129 (60.8)	
≥3 comorbidity, n (%)	57 (35.4)	104 (64.6)	
<b>Type of respiratory support</b>			
IMV, n (%)	103 (26.6)	284 (73.4)	<0.001
CPAP, n (%)	70 (47.9)	76 (52.1)	
HFNC, n (%)	87 (58.8)	61 (41.2)	
Mask with reservoir, n (%)	91 (66.9)	45 (33.1)	
<b>APACHE II, median (IQR)</b>	15 (10-21)	18 (13-24)	<0.001
<b>SOFA, median (IQR)</b>	4 (3-6)	6 (4-9)	<0.001
<b>CO-RADS score*</b>			
CO-RADS 1, n (%)	6 (54.5)	5 (45.5)	0.230
CO-RADS 2, n (%)	37 (52.9)	33 (47.1)	
CO-RADS 3, n (%)	52 (40.3)	77 (59.7)	
CO-RADS 4, n (%)	64 (38.3)	103 (61.7)	
CO-RADS 5, n (%)	161 (46.9)	182 (53.1)	
<b>SARS-Cov-2 variant**</b>			
SARS-COV-2, n (%)	3 (37.5)	5 (62.5)	0.975
Alfa, n (%)	22 (43.1)	29 (56.9)	
Beta, n (%)	9 (42.9)	12 (57.1)	
Delta, n (%)	86 (44.3)	108 (55.7)	
Delta plus, n (%)	14 (38.9)	22 (61.1)	

\*: Evaluated in 720 patients.

\*\*: Evaluated in 310 patients.

COPD: Chronic obstructive pulmonary disease; IMV: Invasive Mechanical Ventilation; CPAP: Continuous Positive Airway Pressure; HFNC: High flow nasal cannula; APACHE II: Acute physiology and chronic health evaluation II; SOFA: Sequential organ failure assessment score; CO-RADS: Coronavirus disease 2019 reporting and data system (CO-RADS); SD: Standard deviation; IQR: Interquartile range.